Liver Cancer: Tislelizumab Immunotherapy Study

We are testing a new immunotherapy for patients with liver cancer and moderate liver function. The study aims to see if it can improve treatment outcomes and quality of life.

>2 years6-10 visitsEfficacy phase (II)No PlaceboStandard MedicinesInjectionHepatologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Tevimbra

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Tislelizumab
Tislelizumab is a cancer immunotherapy substance that helps the immune system attack tumor cells by blocking a protein called PD-1 that restrains immune responses.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Centre Hospitalier Regional D'Angers
Hépato-gastroentérologue oncologue
Angers, France
Hopital De La Croix-Rousse
Hépato-gastroentérologue oncologue
Caluire-et-Cuire, France
Centre Hospitalier Universitaire De Bordeaux
Oncologie digestive
Canéjan, France
Sponsor: Unicancer
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.